Erectile dysfunction (ED) is defined as a persistent inability to attain and maintain an erection sufficient to permit satisfactory sexual performance that often lasts for more than 6 months ([@bibr31-1557988317721643]). It is a common disorder in men older than 40 years, with the highest prevalence in Asian men, as reported in a global study ([@bibr21-1557988317721643]). In Taiwan, the prevalence of ED in men older than 40 years has been reported to be 26.0% to 54.3% ([@bibr16-1557988317721643]; [@bibr23-1557988317721643]; [@bibr43-1557988317721643]). Although the pathophysiology of ED is usually multifactorial, the most common etiology is vasculogenic disorders ([@bibr8-1557988317721643]; [@bibr18-1557988317721643]; [@bibr36-1557988317721643]). Phosphodiesterase type 5 inhibitors (PDE5is), which result in increased arterial blood flow and penile erection, often serve as first-line treatment for patients with ED, due to their convenience and good efficacy ([@bibr14-1557988317721643]; [@bibr32-1557988317721643]). Up to 30% to 40% of patients with ED may not respond sufficiently to the maximum dose of PDE5is ([@bibr32-1557988317721643]).

Traditional second-line treatments including intracavernosal injections, intraurethral injections, or use of vacuum constrictive devices could serve as salvage therapy for patients who failed to respond to PDE5is. If second-line treatments fail or are not preferred by the patients, penile prosthesis implantation is usually the last resort treatment for ED ([@bibr32-1557988317721643]; [@bibr36-1557988317721643]). Although the above treatments are usually effective, they have many drawbacks, such as their invasiveness, inconvenience, or nonnatural status.

Low-intensity extracorporeal shock wave therapy (LI-ESWT), a noninvasive therapy, has been applied recently in the treatment of ED because it can induce neovascularization and increase blood flow in cavernosal tissues to improve erectile function ([@bibr6-1557988317721643]; [@bibr39-1557988317721643]; Vardi, Appel, Kilchevsky, & Gruenwald, 2012). Although most of the published results report that LI-ESWT can be a useful treatment for patients with mild-to-moderate ED, especially those who respond to PDE5is ([@bibr37-1557988317721643]; [@bibr39-1557988317721643], [@bibr40-1557988317721643]), few studies have evaluated the role of LI-ESWT in patients with severe ED who were nonresponders to PDE5is, especially in Asia ([@bibr4-1557988317721643]; [@bibr13-1557988317721643]; [@bibr20-1557988317721643]). An initial report from [@bibr13-1557988317721643] identified that only one third of patients with severe ED were able to recover an erection hard enough for sexual intercourse using LI-ESWT after a PDE5i washout. LI-ESWT was recently reported to improve erectile function independent of the nitric oxide (NO)/cyclic guanosine monophosphate (cGMP) pathway, and it could potentiate its effect in combination with PDE5i use in a type 2 diabetes mellitus rat model ([@bibr1-1557988317721643]). It would be reasonable to combine LI-ESWT and PDE5i to maximize treatment effects in patients with severe ED ([@bibr4-1557988317721643]; [@bibr13-1557988317721643]; [@bibr20-1557988317721643]). The aim of the current study was to evaluate whether combined treatment with LI-ESWT and PED5is could restore erectile function in Taiwanese patients who failed to respond to PDE5is alone.

Methods {#section1-1557988317721643}
=======

This was an open-label single-arm prospective study. Patients who were not able to achieve an erection hard enough for vaginal penetration (erection hardness score, EHS ≦2) after taking a maximal dosage of PDE5is between April 2015 and December 2016 were enrolled from Kaohsiung Medical University--affiliated hospitals, Kaohsiung Municipal Ta-Tung Hospital, and Pingtung Hospital, which are all located in southwestern Taiwan. Eligible subjects were aged more than 20 years and in a stable relationship and had had ED at least 6 months with an insufficient response to any of the PDE5is at a maximal dosage and after adequate education. The PDE5is and dosages used were sildenafil (100 mg), tadalafil (20 mg), and vardenafil (20 mg) with a trial of at least four times, or tadalafil (5 mg) with a trial of at least 28 days ([@bibr32-1557988317721643]). If unrecognized hypogonadism with serum total testosterone levels below 350 ng/dL was noted during initial screening, a testosterone replacement therapy (TRT) trial of at least 3 months was performed first to restore testosterone levels to a normal range ([@bibr2-1557988317721643]; [@bibr42-1557988317721643]). Only those subjects who still failed to respond to PDE5is (EHS ≦2) after their hypogonadism was corrected were enrolled. Subjects were excluded if they had significant coagulopathy, penile anatomical abnormalities, neurological abnormalities, unstable psychiatric disorders, uncorrected hormone abnormalities, clinically significant medical diseases, or a history of extensive pelvic surgery or irradiation. The study protocol was approved by the Institutional Review Board of Kaohsiung Medical University Hospital. Each participant provided and signed informed consent.

Initial Screening {#section2-1557988317721643}
-----------------

All participants were assessed using a structured questionnaire to collect their demographic information and detailed medical, surgical, and psychosexual history. The well-known risk factors for ED, including diabetes mellitus, hypertension, hyperlipidemia, cardiovascular disease, stroke, alcohol drinking, and cigarette smoking, were completely reviewed. Subjects were classified as alcohol drinkers or cigarette smokers if they had regularly consumed any alcoholic beverage ≥1 time per week, or had smoked ≥10 cigarettes per week, respectively, for at least 6 months. Current users were those who were still using any of these substances within 1 year before the interview ([@bibr25-1557988317721643], [@bibr24-1557988317721643]). In addition to a detailed physical examination, 20-mL blood samples were drawn from all participants between 8:00 AM and 11:00 AM, after an overnight fasting of more than 8 hr, for analyses of serum glucose, lipid panels, routine biochemical profiles, and total testosterone levels. Erectile function of each participant under a maximal dosage of PDE5i was assessed using EHS and an abridged, 5-item version of the International Index of Erectile Function (IIEF-5).

Treatment Protocol {#section3-1557988317721643}
------------------

All participants received LI-ESWT (Duolith SD1 T-TOP, Storz, Switzerland) once weekly for 12 weeks in an outpatient setting, without local or systemic anesthesia. At each treatment session, a total of 3,000 shocks of LI-ESWT were applied at six sites (500 shocks per site at the bilateral distal and proximal parts of the corpus cavernosa and the bilateral crural areas) with an energy setting of 0.15 mJ/mm^2^ intensity at a frequency of 240 shocks/min. Since the penetration depth of LI-ESWT is enough to cover the bilateral corpus cavernosa, the level of application at bilateral sites differed to achieve maximal penile treatment. During the LI-ESWT treatment period, all patients remained on their regular high on-demand or once-daily PDE5i dosing schedules. In subjects with concomitant hypogonadism, TRT was also performed simultaneously, unless their condition had improved.

Outcome Measures of LI-ESWT {#section4-1557988317721643}
---------------------------

Erectile function of the participants was reassessed using EHS and IIEF-5 at 1 and 3 months after a complete course of LI-ESWT and with regular PDE5is use. The main outcome measure for efficacy of LI-ESWT was EHS. Success of treatment was defined as EHS 3 or greater, which indicated the regaining of an erection sufficient for vaginal penetration ([@bibr30-1557988317721643]). During treatment, any adverse effect associated with LI-ESWT, like penile pain or ecchymosis, was recorded.

Statistical Analysis {#section5-1557988317721643}
--------------------

Quantitative data were represented as mean ± standard deviation (SD) and median with interquartile range (IQR), unless otherwise indicated. Categorical data were represented by number (n) and percentage. To quantify the difference between subjects with and without response to LI-ESWT, qualitative variables were compared using the chi-square test and Fisher's exact test, while quantitative variables were compared using Student's *t*-test. For all statistical analyses, *p* \< .05 was considered statistically significant. All statistical operations were performed using SPSS version 18.0 (SPSS Inc., Chicago, IL, U.S.A.).

Results {#section6-1557988317721643}
=======

A total of 52 patients with a mean age of 60.1 ± 11.5 years (median: 63.0 years, IQR: 52.5--68.0, range: 33.0--79.0) were enrolled. The mean history of ED was 38.3 ± 26.9 months (median: 33.0 months, IQR: 18.0--60.0). More than half of the patients had been diagnosed as having hypertension (51.9%) and hyperlipidemia (59.6%). The prevalence of diabetes mellitus and cardiovascular disease was 26.3% and 13.5%, respectively. The mean serum total testosterone level was 501.4 ± 183.6 ng/dL (median: 476.5 ng/dL, IQR: 378.4--611.2). Nine of the 52 patients (17.3%) had serum total testosterone levels below 350 ng/dL ([Table 1](#table1-1557988317721643){ref-type="table"}).

###### 

Baseline Characteristics of the Study Population (*n* = 52).

![](10.1177_1557988317721643-table1)

  Parameter                              No (%)      Mean ± SD       Median   IQR
  -------------------------------------- ----------- --------------- -------- --------------
  Age (years)                                        60.1 ± 11.5     63.0     52.5--68.0
  Body mass index (kg/m^2^)                          25.3 ± 2.3      25.1     23.5--26.2
  Erectile dysfunction history (month)               38.3 ± 26.9     33.0     18.0--60.0
  Diabetes mellitus                      14 (26.3)                            
  Hypertension                           27 (51.9)                            
  Dyslipidemia                           31 (59.6)                            
  Cardiovascular disease                 7 (13.5)                             
  Stroke                                 0 (0)                                
  Current smoking                        11 (21.2)                            
  Current alcohol drinking               9 (17.3)                             
  Laboratory data                                                             
  Testosterone (ng/dL)                               501.4 ± 183.6   476.5    378.4--611.2
  Triglycerides (mg/dL)                              112.1 ± 57.4    90.5     73.8--154.8
  Total cholesterol (mg/dL)                          191.1 ± 33.9    191.5    161.8--211.5
  High-density lipoprotein (mg/dL)                   46.9 ± 13.6     45.3     35.4--55.3
  Fasting sugar (mg/dL)                              114.2 ± 36.6    102.5    94.8--116.5

*Note*. IQR = interquartile range; SD = standard deviation.

With regard to medical treatment with an insufficient response (EHS ≦2) before LI-ESWT, 40 (76.9%), 11 (21.2%), and 2 (3.8%) patients failed to respond to a maximal dosage of sildenafil (100 mg), tadalafil (20 mg), and vardenafil (20 mg), individually, in a trial of at least four times. In addition, 28 (53.8%) patients also failed to respond to a tadalafil (5 mg) daily dosage in a trial of at least 28 days. Nearly half of the study population (48.1%) had tried different kinds of PDE5is before LI-ESWT, but still failed. In nine patients (17.3%) with serum total testosterone levels below 350 ng/dL, as noted in the initial screening, a TRT trial of at least 3 months was performed first, in addition to PDE5is use. The nine patients still had an insufficient response (EHS ≦2), even after serum total testosterone levels returned to normal. During LI-ESWT treatment, those subjects continued TRT in addition to PDE5is use ([Table 2](#table2-1557988317721643){ref-type="table"}).

###### 

Medical Treatments With Insufficient Response (Erection Hardness Score ≦2) Before Shockwave Therapy.

![](10.1177_1557988317721643-table2)

  Phosphodiesterase type 5 inhibitors                                       *N* (%)      Adjuvant TRT (*N*)
  ------------------------------------------------------------------------- ------------ --------------------
  Sildenafil (100 mg)                                                       19 (36.6)    2
  Tadalafil (5 mg) daily use                                                8 (15.4)     0
  Sildenafil (100 mg) and vardenafil (20 mg)                                1 (1.9)      1
  Sildenafil (100 mg) and tadalafil (20 mg)                                 4 (7.7)      1
  Sildenafil (100 mg) and tadalafil (5 mg) daily use                        12 (23.1)    3
  Tadalafil (20 mg) and tadalafil (5 mg) daily use                          4 (7.7)      1
  Sildenafil (100 mg), vardenafil (20 mg), and tadalafil (5 mg) daily use   1 (1.9)      0
  Sildenafil (100 mg), tadalafil (20 mg), and tadalafil (5 mg) daily use    3 (5.8)      1
  Total                                                                     52 (100.0)   9

*Note*. TRT = testosterone replacement therapy.

Changes in erectile function at the 1-month and 3-month follow-up after 12 weeks of LI-ESWT revealed the following. The mean value of the EHS score increased from 1.7 ± 0.4 to 2.8 ± 0.8, with a difference of 1.1 ± 0.7 (*p* \< .001) at the 1-month follow-up. Thirty-five of 52 patients (67.3%) had a successful response to LI-ESWT, with 28 (53.8%) achieving EHS 3, and 7 (13.5%) achieving EHS 4, which indicated sufficient erections for vaginal penetration during sexual intercourse under PDE5is use. The mean value of the IIEF-5 increased from 9.6 ± 2.9 to 15.0 ± 5.0 points, with a difference of 5.4 ± 3.7 ( *p* \< .001) at the 1-month follow-up. The improvement of EHS and IIEF-5 were persistent at the 3-month follow-up ([Table 3](#table3-1557988317721643){ref-type="table"}). No adverse effect associated with LI-ESWT, like penile pain or ecchymosis, was reported in any of the patients.

###### 

Change of Erectile Function After Shockwave Therapy at the 1-Month and 3-Month Follow-up.

![](10.1177_1557988317721643-table3)

                            Baseline    1 month after treatment   Difference                                                         3 months after treatment   Difference
  ------------------------- ----------- ------------------------- ------------------------------------------------------------------ -------------------------- ------------------------------------------------------------------
  Erectile hardness score   1.7 ± 0.4   2.8 ± 0.8                 1.1 ± 0.7^[a](#table-fn4-1557988317721643){ref-type="table-fn"}^   2.7±0.8                    1.0 ± 0.7^[a](#table-fn4-1557988317721643){ref-type="table-fn"}^
  1                         14 (26.9)   3 (5.8)                                                                                      3 (5.8)                    
  2                         38 (73.1)   14 (26.9)                                                                                    16 (30.8)                  
  3                         0 (0)       28 (53.8)                                                                                    27 (51.9)                  
  4                         0 (0)       7 (13.5)                                                                                     6 (11.5)                   
  IIEF-5 score              9.6 ± 2.9   15.0 ± 5.0                5.4 ± 3.7^[a](#table-fn4-1557988317721643){ref-type="table-fn"}^   15.4 ± 4.9                 5.8 ± 3.4^[a](#table-fn4-1557988317721643){ref-type="table-fn"}^

*Note.* IIEF-5 = 5-item version of the International Index of Erectile Function.

*p* \< .001.

Clinical characteristics and laboratory data of subjects with and without a response to LI-ESWT at the 1-month follow-up revealed no significant difference in age, body mass index (BMI), history of ED, comorbidities, current cigarette smoking and alcohol drinking, or laboratory data ([Table 4](#table4-1557988317721643){ref-type="table"}). Subjects with more severe ED at baseline had a significantly low response rate to LI-ESWT (EHS1: 35.7% vs. EHS2: 78.9%, *p* = .005). IIEF-5 score at baseline was also significantly lower in subjects without response to LI-ESWT compared to those with response (8.1 ± 2.8 vs. 10.4 ± 2.7, *p* = .01). The result is still significant even after adjusting for age, BMI, history of ED, comorbidities, and current cigarette smoking and alcohol drinking (EHS1 vs. EHS2, adjusted odds ratio: .08, 95% CI\[0.013, 0.520\], *p* = .008).

###### 

Comparison of Clinical Characteristics and Laboratory Data Between Subjects With and Without Response to Shockwave Therapy.

![](10.1177_1557988317721643-table4)

  --------------------------------------------------------------------------------------------------------------------
  Parameter                                         Subjects without response\   Subjects with response\   *p* value
                                                    (*N* = 17)                   (*N* = 35)                
  ------------------------------------------------- ---------------------------- ------------------------- -----------
  Age (years)                                       61.4 ± 10.5                  59.4 ± 12.1               .57

  Body mass index (kg/m2)                           25.8 ± 2.9                   25.1 ± 2.0                .29

  Duration of erectile dysfunction (month)          39.6 ± 24.1                  37.6 ± 27.1               .80

  Severity of erectile dysfunction, *n* (%)                                                                

  Initial EHS1                                      9 (64.3)                     5 (35.7)                  .005

  Initial EHS2                                      8 (21.1)                     30 (78.9)                 

  IIEF-5                                            8.1 ± 2.8                    10.4 ± 2.7                .01

  Diabetes mellitus, *n* (%)                        7 (50.0)                     7 (50.0)                  .11

  Diabetes mellitus with insulin control, *n* (%)   3 (60.0)                     2 (40.0)                  .37

  Hypertension, *n* (%)                             8 (29.6)                     19 (70.4)                 .63

  Dyslipidemia, *n* (%)                             11 (35.5)                    20 (64.5)                 .60

  Cardiovascular disease, *n* (%)                   2 (28.6)                     5 (71.4)                  .80

  Stroke, *n* (%)                                   0 (0)                        0 (0)                     

  Hypogonadism, *n* (%)                             4 (44.4)                     5 (55.6)                  .41

  Current smoking, *n* (%)                          3 (27.3)                     8 (72.7)                  .19

  Current alcohol drinking, *n* (%)                 1 (11.1)                     8 (88.9)                  .13

  Number of comorbidities                           2.0 ± 1.3                    1.7 ± 1.2                 .29

  Laboratory data                                                                                          

  Total testosterone (ng/dL)                        492.9 ± 198.3                505.6 ± 178.9             .82

  Triglycerides (mg/dL)                             104.9 ± 56.4                 115.9 ± 58.5              .52

  Total cholesterol (mg/dL)                         189.0 ± 35.4                 192.2 ± 33.6              .76

  High-density lipoprotein (mg/dL)                  47.4 ± 17.4                  46.6 ± 11.5               .86

  Fasting blood sugar (mg/dL)                       132.4 ± 54.7                 104.8 ± 16.9              .058
  --------------------------------------------------------------------------------------------------------------------

*Note.* EHS = erection hardness score; IIEF-5 = 5-item version of the International Index of Erectile Function.

[Figure 1](#fig1-1557988317721643){ref-type="fig"} presents the improvement in erectile function 1 month after LI-ESWT in patients with different initial EHS scores. Of 38 subjects with an initial EHS 2, 23 (60.5%) achieved EHS 3 and 7 (18.4%) achieved EHS 4. However, only 5 of 14 subjects (35.7%) with an initial EHS 1 could achieve EHS 3, and none could achieve EHS 4 ([Figure 1](#fig1-1557988317721643){ref-type="fig"}). In 35 subjects who responded to LI-ESWT, the mean value of the EHS score increased from 1.9 ± 0.4 to 3.2 ± 0.4 at the 1-month follow-up and 3.1 ± 0.5 at the 3-month follow-up, respectively (both *p* \< .001). The mean value of the IIEF-5 also increased from 10.4 ± 2.7 to 17.4 ± 3.6 and 17.7 ± 3.2 points, respectively (both *p* \< .001; [Figure 2](#fig2-1557988317721643){ref-type="fig"}). Thirty-three of the 35 (94.3%) subjects who responded to LI-ESWT could still achieve EHS 3 or greater with PDE5is use at the 3-month follow-up ([Table 3](#table3-1557988317721643){ref-type="table"}).

![Improvement of erectile function after shockwave therapy in patients with different initial erection hardness scores (EHSs).](10.1177_1557988317721643-fig1){#fig1-1557988317721643}

![Improvement of erectile function in subjects who responded to shockwave therapy at the 1-month and 3-month follow-up (*n* = 35).\
*Note.* EHS = erection hardness score; IIEF-5 = 5-item version of the International Index of Erectile Function.](10.1177_1557988317721643-fig2){#fig2-1557988317721643}

Discussion {#section7-1557988317721643}
==========

In the current study, nearly two thirds of the ED patients (67.3%) who failed to respond to PDE5is (EHS ≦2) could achieve an erection sufficient for vaginal penetration during sexual intercourse (EHS ≧3) after 12 weeks of LI-ESWT treatment; 94.3% of those subjects were able to maintain their erectile function (EHS ≧3) at the 3-month follow-up. In addition, no one reported any adverse effect associated with LI-ESWT.

PDE5is have been widely accepted as first-line treatment for ED that can facilitate erection by inhibiting the PDE5 enzyme. This enzyme is specifically responsible for the degradation of cGMP in the cavernous smooth muscles. Use of PDE5is can result in prolonged cGMP activity, which further decreases intracellular calcium concentrations and maintains smooth muscle relaxation, leading to rigid penile erection. Up to 30% to 40% of patients with ED may not sufficiently respond to a maximum dose of PDE5is ([@bibr32-1557988317721643]). Adequate education for the optimization of PDE5i use, lifestyle modification, controlling of vascular and psychosocial risk factors, switching to another type or daily dosage of PDE5i, and additional TRT for unrecognized hypogonadism are common strategies for PDE5i nonresponders ([@bibr2-1557988317721643]; [@bibr9-1557988317721643]; [@bibr26-1557988317721643]; [@bibr32-1557988317721643]), but their efficacy is usually unsatisfactory.

All of the patients in the current study had received adequate education for the optimization of their PDE5i use, and their hypogonadism was corrected by TRT. Nearly half (48.1%) had tried a different kind of PDE5i before enrolling in this study. Previous reports identified that only a small percentage (5%--12%) of nonresponders to one PDE5i could be satisfactorily rescued with another ([@bibr5-1557988317721643]; [@bibr32-1557988317721643]). Although daily dosing of PDE5is has been reported to have a better rescue rate ([@bibr19-1557988317721643]; [@bibr29-1557988317721643]; [@bibr32-1557988317721643]), more than half of the patients (53.8%) in the current study failed to respond to daily dosing of tadalafil (5 mg) in a trial of at least 28 days. The salvage rate of TRT in hypogonadal men who failed to respond to PDE5is have been reported with variable ranging from 32% to 100% ([@bibr17-1557988317721643]). In the meta-analysis from [@bibr7-1557988317721643], TRT was only reported to be positive on PDE5is outcome in uncontrolled studies, but not in placebo-controlled ones. Nine hypogonadal patients in the current study had still failed to respond to PDE5is use even after a TRT trial of at least 3 months to restore their testosterone levels to a normal range. Therefore, this study population represented true nonresponders to PDE5is, which is a significant challenge to manage in clinical practice.

LI-ESWT, a noninvasive treatment that can increase intracavernosal neovascularization, has become a novel, alternative treatment for ED. The mechanism by which LI-ESWT induces angiogenesis has been evaluated in a number of recent studies. [@bibr28-1557988317721643] demonstrated that extracorporeal shockwaves at a low energy density could enhance endothelial nitric oxide synthase (eNOS) activity and induce enzymatic NO production in human umbilical vein endothelial cells. [@bibr41-1557988317721643] identified that LI-ESWT stimulated the expression of angiogenesis-related growth factors and endothelial cell proliferation factors, including NOS, vascular endothelial growth factors (VEGF), and proliferating cell nuclear antigen (PCNA) in a rabbit model. It has been hypothesized that when appropriate energy from LI-ESWT accumulates within the targeted tissues, it will induce shear stress and intracellular microtrauma, and then stimulate eNOS and release of VEGF and PCNA, resulting in neovascularization. This hypothesis has been proven in several animal studies ([@bibr11-1557988317721643], [@bibr12-1557988317721643]; [@bibr38-1557988317721643]). Another possible mechanism through which LI-ESWT can improve ED may be mediated by recruitment of endogenous mesenchymal stem cells. [@bibr33-1557988317721643] reported that LI-ESWT could recruit endogenous mesenchymal stem cells to promote regeneration of neuronal nitric oxide synthase (nNOS)--positive nerves, endothelium, and smooth muscle in the penis, which further ameliorated ED in a diabetes mellitus rat model. [@bibr22-1557988317721643] reported that LI-ESWT could recruit endogenous progenitor cells and activate Schwann cells to promote angiogenesis and tissue and nerve generation in a rat model of pelvic neurovascular injuries. [@bibr1-1557988317721643] suggested that the effects of LI-ESWT may not be mediated by a NO/cGMP-dependent mechanism in a rat model of type 2 diabetes. Further investigation is needed to evaluate the efficacy of LI-ESWT in patients with different etiologies of ED and to elucidate possible underlying mechanisms.

Although LI-ESWT has been widely used in urology for Peyronie's disease and chronic pelvic pain ([@bibr10-1557988317721643]), Vardi et al. first reported the experience of using LI-ESWT in the treatment of ED in 2010 ([@bibr39-1557988317721643]). Since that, more and more studies on LI-ESWT have reported positive results in the improvement of ED. The results of the updated meta-analysis of [@bibr27-1557988317721643], which analyzed 14 studies (7 randomized controlled trials and 7 cohort studies, n = 833)suggested that LI-ESWT could significantly improve EHS and IIEF in ED patients, although variation in patient's baseline characteristics, LI-ESWT's setup parameters, and treatment protocols existed. Few studies have evaluated the role of LI-ESWT in the treatment of patients with ED who were nonresponders to PDE5is, especially in Asia. Only five studies with limited patient numbers were found in a literature review ([Table 5](#table5-1557988317721643){ref-type="table"}; [@bibr3-1557988317721643]; [@bibr6-1557988317721643]; [@bibr13-1557988317721643]; [@bibr20-1557988317721643]; [@bibr35-1557988317721643]), and only one study was a randomized controlled trial ([@bibr20-1557988317721643]). Most of these patients had concomitant PDE5is use during and after LI-ESWT, and up to 50% to 72.4% of patients were converted to PDE5i responders (EHS ≧3) after LI-ESWT treatment. The improvement of IIEF-EF or IIEF-5 scores in those studies were all higher than 4 points that were suggested as the minimal clinically important differences (MCIDs) by Rosen et al. in the evaluation of treatment efficacy for ED patients ([@bibr34-1557988317721643]). In the current study, nearly two thirds of the patients (67.3%) were converted to PDE5i responders after 12 weeks of LI-ESWT treatment. The mean improvement of IIEF-5 score was 5.4 ± 3.7 at the 1-month follow-up. The current results are compatible with those of previous studies ([Table 5](#table5-1557988317721643){ref-type="table"}). In addition, initial severity of ED was identified as the important predictor of successful response to LI-ESWT. In patients with initial EHS2, 78.9% were able to achieve EHS ≧3, compared to 35.7% of subjects with initial EHS1 (*p* = .005; [Table 4](#table4-1557988317721643){ref-type="table"}). IIEF-5 score at baseline was also significantly higher in subjects with response to LI-ESWT compared to those without response (10.4 ± 2.7 vs. 8.1 ± 2.8, *p* = .01). No statistically significant difference in age, BMI, duration of ED, comorbidities, and personal habits was identified in the current study when comparing responders to nonresponders to LI-ESWT. Bechara et al. reported similar results in their 12-month follow-up of LI-ESWT in patients who were nonresponders to PDE5is ([@bibr3-1557988317721643]). [@bibr15-1557988317721643] reported that age and the number of comorbidities were negative predictive factors of therapeutic response to LI-ESWT in a population of ED patients composed of responders and nonresponders to PDE5is. Since different generators and protocols of LI-ESWT were used in those studies, further studies are needed to compare the efficacy of different generators of LI-ESWT and to determine an adequate therapeutic protocol and important predictors of successful response to LI-ESWT in patients with different etiologies of ED.

###### 

Literature Review of Studies About Li-ESWT in Patients With Erectile Dysfunction Who Were Nonresponders to PDE5i.

![](10.1177_1557988317721643-table5)

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                        Setup of LI-ESWT   Protocol of LI-ESWT   Combined PDE5i   Outcomes                                                                                                                                                                            
  ---------------------------- ------------------ --------------------- ---------------- ------------- ------ ------- ----- --- --- ---------------------------------------------------------- ----- ----- ----- ----------------------------------------------------------- --------------------------------------------------------------------
  [@bibr13-1557988317721643]   Cohort study       Omnispec ED 1000      29               1, 2          0.09   1,500   120   2   5   9^[a](#table-fn7-1557988317721643){ref-type="table-fn"}^   Yes   No    Yes   34.5% without PDE5i (1month); 72.4% with PDE5i (2 months)   IIEF-EF: +3.5 without PDE5i (1 month); +10.0 with PDE5i (2 months)

  [@bibr35-1557988317721643]   Cohort study       Renova NR             31               1,3           0.09   3,600   NA    1   4   4                                                          Yes   No    NA    NA                                                          IIEF-EF: +4.6 (1 month); +4.5 (3 months)

  [@bibr6-1557988317721643]    Cohort study       Duolith SD1           30               1,4           0.25   3,000   360   2   4   6                                                          NA    NA    NA    50% (6 weeks)                                               IIEF-5 improvement ≧5: 60% (6 weeks)

  Kitrey et al., 2015          RCT                Omnispec ED 1000      53               1             0.09   1,500   120   2   5   9^[a](#table-fn7-1557988317721643){ref-type="table-fn"}^   No    Yes   Yes   54.1% (1 month)                                             IIEF-EF: +6 (1 month)

  [@bibr3-1557988317721643]    Cohort study       Renova NR             40               3, 6, 9, 12   0.09   3,600   NA    1   4   4                                                          No    Yes   Yes   60% (3 months)                                              Responders: IIEF-EF: +9.3 (3 month); +9.1 (12 months)

  Our study                    Cohort study       Duolith SD1           52               1, 3          0.15   3,000   240   1   6   12                                                         No    Yes   Yes   67.3% (1 month)\                                            IIEF-5 improvement: +5.4 (1 month); +5.8( 3 months)
                                                                                                                                                                                                                 63.4% (3 months)                                            
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*Note.* EHS = erection hardness score; IIEF-EF = International Index of Erectile Function-Erectile Function; IIEF-5 = 5-item version of the International Index of Erectile Function; LI-ESWT = low-intensity extracorporeal shock wave therapy; NA = not available; PDE5i = phosphodiesterase type 5 inhibitor; RCT = randomized controlled trial.

Include a 3-week interval without treatment.

In the meta-analysis from Lu et al. ([@bibr27-1557988317721643]), the therapeutic efficacy of LI-ESWT in ED patients seems to last at least 3 months. In the literature review of LI-ESWT in the treatment of patients who were nonresponders to PDE5is, most of the studies reported similar results ([Table 5](#table5-1557988317721643){ref-type="table"}). In the current study, 33 of the 35 (94.3%) subjects who responded to LI-ESWT could still maintain EHS3 or greater with PDE5is use at the 3-month follow-up ([Table 3](#table3-1557988317721643){ref-type="table"}). The improvement of IIEF-5 score was also persistent at the 3-month follow-up ([Figure 2](#fig2-1557988317721643){ref-type="fig"}). Recently, Bechara et al. reported that 91.7% of responders to LI-ESWT, who were nonresponders to PDE5is before, could still maintain their responses after the 12-month follow-up ([@bibr3-1557988317721643]). Further large studies, especially randomized controlled trials, are needed to elucidate the long-term efficacy and cost-effectiveness of LI-ESWT in the treatment of ED patients.

There are several limitations to the current study. First, this study design is a single-arm prospective study without controls or comparison group with other form of therapy. Second, the patient number was limited, so it is difficult to compare the efficacy of LI-ESWT in different etiologies of ED. Third, the follow-up period was only 3 months, so the long-term efficacy of LI-ESWT could not be evaluated. Further large and long-term studies are needed to clarify these questions.

In conclusion, LI-ESWT can serve as a salvage therapy in ED patients who failed to response to PDE5is. Nearly two thirds of the patients in the current study could be converted to PDE5i responders (EHS ≧3) and 94.3% could maintain their erectile function at the 3-month follow-up. Initial severity of ED was the only significant predictor of successful response to LI-ESWT. Further studies are needed to compare the efficacy of different generators of LI-ESWT and to determine an adequate therapeutic protocol and important predictors in patients with different etiologies of ED.
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